DETROIT, MICH. ~ Starting in 2027, Novo Nordisk will cut the costs of monthly supplies of three GLP-1’s that help with diabetes and weight-loss. A four-week supply of Ozempic, Wegovy, and Rybelsus will all be priced at $675 beginning on Jan. 1 next year due to competition from Eli Lilly. Customers will save hundreds with these cuts, as the current price of Wegovy is more than double the new rate. These prices will only change for those with linked insurance plans, not for those who pay with cash.
